Abstracts

Out-of-Pocket Payments for PrEP Ancillary Services Among US Commercially-Insured Persons, 2017-2021

Background: In June 2019, HIV preexposure prophylaxis (PrEP) received a grade A recommendation from the U.S. Preventive Services Task Force (USPSTF). Under the Affordable Care Act, private health plans and Medicaid expansion programs must cover the costs of all PrEP services without any patient cost-sharing starting in January 2021, including PrEP medications and ancillary services…

Behavioral and Structural Interventions for PrEP Adherence Among Young Female Sex Workers in Kenya

Background: In Kenya, estimated HIV incidence is substantially higher among young female sex workers (YFSW) compared to similar-age women not engaged in sex work (2.2% vs. 0.15%). Pre-exposure prophylaxis (PrEP) for HIV prevention is recommended for at-risk populations, but its effectiveness requires consistent access and adherence. We assessed the effectiveness of two behavioral and structural…

First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care

Background: Long-acting cabotegravir (CAB-LA) PrEP is highly effective but delayed diagnoses and INSTI resistance were observed with incident infections in registrational trials. As CAB is scaled up, continued vigilance is needed to assess HIV acquisition, pharmacokinetics (PK), resistance, and ART outcomes after infections. We report the first case outside of trials, to our knowledge, of…

Effectiveness of Using HIV Self-Tests as an Incentive for Testing Within Assisted Partner Services

Background: There is a need for interventions to increase the success of offering HIV self-testing (HIVST) within assisted partner services (APS) in low resource settings. Financial incentives have shown success in increasing HIV testing rates but results on non-monetary incentives remain mixed. We investigated the effectiveness of offering an additional HIV self-test as an incentive…

Method for Analyzing Cabotegravir and Rilpivirine in Hair May Help Identify Risk Factors for Failure

Background: Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) is a promising approach to improve virologic suppression, including among those with adherence challenges. However, resistance can occur among virologic failures. Risk factors for virologic failure defined in the clinical trials include high body mass index (BMI) which can decrease CAB levels, low RPV troughs, HIV subtypes…